Precision Medicine in Lung Cancer Treatment

Surg Oncol Clin N Am. 2020 Jan;29(1):15-21. doi: 10.1016/j.soc.2019.08.002. Epub 2019 Oct 16.

Abstract

Lung cancer remains second most common cancer in men and women in the United States. More than 50% of patients are diagnosed in the advanced stage. Traditionally, chemotherapy has been the backbone of management of stage IV lung cancer. A better understanding of the molecular pathogenesis has led to rapid development of targeted therapy and immunotherapy. This has led to significant improvement in survival of patients with lung cancer stages III to IV. These drugs are being studied in early stage lung cancer. Several trials are ongoing to improve the survival and quality of life of our patients.

Keywords: Clinical trials; Immunotherapy; Lung cancer; Molecular testing; Targeted therapy.

Publication types

  • Review

MeSH terms

  • Antineoplastic Agents / therapeutic use*
  • Biomarkers, Tumor / genetics*
  • Humans
  • Lung Neoplasms / drug therapy*
  • Lung Neoplasms / genetics
  • Molecular Targeted Therapy / methods*
  • Pharmacogenetics / methods*
  • Precision Medicine / methods
  • Precision Medicine / trends*

Substances

  • Antineoplastic Agents
  • Biomarkers, Tumor